子宫腺肌症药物治疗的研究进展  

Research progress of drug therapy for adenomyosis

作　　者：丁梦凯 顾振鹏[2] 刘志慧[2] 崔金秀[2] 孙政 Ding Mengkai;Gu Zhenpeng;Liu Zhihui;Cui Jinxiu;Sun Zheng(The First Clinical Medical College,Binzhou Medical College,Binzhou 256603,China;Department of Gynecology,Affiffiffi liated Hospital of Binzhou Medical College,Binzhou 256699,China)

机构地区：[1]滨州医学院第一临床医学院,山东滨州256603 [2]滨州医学院附属医院妇科,山东滨州256699

出　　处：《实用妇科内分泌电子杂志》2022年第2期47-50,共4页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：子宫腺肌症是一种主要表现为月经异常、痛经和不孕的良性子宫疾病。随着辅助技术的发展与成熟,子宫腺肌症的流行病学概况也有了一定改变。患者逐渐趋向于年轻化,越来越多的育龄期妇女深受其害。因此,满足保持或恢复生育能力和控制临床症状的需求,针对患者情况提供个性化治疗方案,是当下治疗子宫腺肌症的首要任务。本文主要阐述子宫腺肌症患者药物治疗的研究进展及新思路。Adenomyosis is a disease characterized by menstrual abnormalities,pain and infertility.With the development and maturity of assistive technology,uterine gland The epidemiological profifi le of myopathy has also changed to some extent.Patients tend to be younger and more and more childbearing age Women suffer.Therefore,it is necessary to meet the needs of maintaining or restoring fertility and controlling clinical symptoms Providing personalized treatment is the primary task in the treatment of adenomyosis.This paper mainly expounds the uterus Research progress and new ideas of drug therapy for patients with adenomyosis.

关 键 词：子宫腺肌症 促性腺激素类似物 左炔诺孕酮宫内缓释系统 中药 药物治疗 

分 类 号：R711.74[医药卫生—妇产科学]